JP2022041802A5 - - Google Patents

Download PDF

Info

Publication number
JP2022041802A5
JP2022041802A5 JP2020187708A JP2020187708A JP2022041802A5 JP 2022041802 A5 JP2022041802 A5 JP 2022041802A5 JP 2020187708 A JP2020187708 A JP 2020187708A JP 2020187708 A JP2020187708 A JP 2020187708A JP 2022041802 A5 JP2022041802 A5 JP 2022041802A5
Authority
JP
Japan
Prior art keywords
antagonist
weeks
administered
pharmaceutical composition
pruritus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020187708A
Other languages
English (en)
Japanese (ja)
Other versions
JP7548784B2 (ja
JP2022041802A (ja
Filing date
Publication date
Priority claimed from JP2020551453A external-priority patent/JP6799831B1/ja
Application filed filed Critical
Priority to JP2020187708A priority Critical patent/JP7548784B2/ja
Publication of JP2022041802A publication Critical patent/JP2022041802A/ja
Publication of JP2022041802A5 publication Critical patent/JP2022041802A5/ja
Application granted granted Critical
Publication of JP7548784B2 publication Critical patent/JP7548784B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020187708A 2020-09-01 2020-11-11 Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物 Active JP7548784B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020187708A JP7548784B2 (ja) 2020-09-01 2020-11-11 Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020551453A JP6799831B1 (ja) 2020-09-01 2020-09-01 Il−31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物
PCT/JP2020/032987 WO2022049614A1 (ja) 2020-09-01 2020-09-01 Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物
JP2020187708A JP7548784B2 (ja) 2020-09-01 2020-11-11 Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020551453A Division JP6799831B1 (ja) 2020-09-01 2020-09-01 Il−31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物

Publications (3)

Publication Number Publication Date
JP2022041802A JP2022041802A (ja) 2022-03-11
JP2022041802A5 true JP2022041802A5 (https=) 2023-07-26
JP7548784B2 JP7548784B2 (ja) 2024-09-10

Family

ID=73741045

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551453A Active JP6799831B1 (ja) 2020-09-01 2020-09-01 Il−31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物
JP2020187708A Active JP7548784B2 (ja) 2020-09-01 2020-11-11 Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020551453A Active JP6799831B1 (ja) 2020-09-01 2020-09-01 Il−31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物

Country Status (10)

Country Link
US (1) US20230391878A1 (https=)
EP (1) EP4209227A4 (https=)
JP (2) JP6799831B1 (https=)
KR (2) KR102269716B1 (https=)
CN (1) CN116096411A (https=)
AU (1) AU2020466800A1 (https=)
CA (1) CA3189847A1 (https=)
IL (1) IL300694A (https=)
MX (1) MX2023002482A (https=)
WO (1) WO2022049614A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170134748A (ko) 2015-04-14 2017-12-06 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CN114728064B (zh) 2019-11-20 2025-05-06 中外制药株式会社 含抗体制剂
WO2025167991A1 (zh) * 2024-02-07 2025-08-14 武汉人福创新药物研发中心有限公司 一种靶向il-31ra的抗体或其抗原结合片段及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
ATE455852T1 (de) 1999-06-02 2010-02-15 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
CA2418835A1 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
JP2002338476A (ja) * 2001-05-21 2002-11-27 Health Factor Kenkyusho:Kk 腎透析に伴う痒みの予防治療剤
AU2003280410B8 (en) 2002-01-18 2009-04-23 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
JP2007527712A (ja) 2004-02-12 2007-10-04 レキシコン・ジェネティクス・インコーポレーテッド 新規な遺伝子破壊、これに関する組成物と方法
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
US20060188500A1 (en) 2005-02-14 2006-08-24 Leung Donald Y Methods of predicting therpeutic response in atopic dermatitis to IL-31 antagonists
JP2008530132A (ja) 2005-02-14 2008-08-07 ザイモジェネティクス, インコーポレイテッド Il−31raアンタゴニストを用いて皮膚障害を治療する方法
CN102321174B (zh) 2005-05-06 2013-10-16 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
CN101589060A (zh) * 2006-01-10 2009-11-25 津莫吉尼蒂克斯公司 使用il-31拮抗剂在神经元性组织中治疗疼痛和炎症的方法
WO2007133816A2 (en) 2006-01-10 2007-11-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
WO2007142325A1 (ja) 2006-06-08 2007-12-13 Chugai Seiyaku Kabushiki Kaisha 炎症性疾患の予防または治療剤
DK2594586T3 (en) 2006-09-01 2014-11-17 Zymogenetics Inc Monoclonal il-31 antibodies and methods of use thereof
CN104162155A (zh) 2007-12-05 2014-11-26 中外制药株式会社 搔痒症治疗药
CA2708532C (en) 2007-12-05 2018-06-05 Chugai Seiyaku Kabushiki Kaisha Anti-il31ra antibody and use thereof
EP2796466B1 (en) 2007-12-07 2017-11-22 ZymoGenetics, Inc. Humanized antibody molecules specific for IL-31
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
TW201537175A (zh) * 2013-06-28 2015-10-01 Chugai Pharmaceutical Co Ltd 預測罹患具皮膚搔癢之疾病的患者對il-31拮抗劑之治療的反應之方法
WO2015025767A1 (ja) * 2013-08-21 2015-02-26 久光製薬株式会社 貼付剤
US20190135804A1 (en) * 2017-11-03 2019-05-09 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Compositions and methods for the inhibition of pruritus
KR102156932B1 (ko) * 2017-11-23 2020-09-17 주식회사 헬릭스미스 천연추출물을 포함하는 소양증의 예방 또는 치료용 조성물
IL326629A (en) * 2018-04-25 2026-04-01 Kiniksa Pharmaceuticals Ltd Treatment of skin diseases or disorders through administration of anti-OSMR BETA antibody

Similar Documents

Publication Publication Date Title
JP2022041802A5 (https=)
Kuriyama et al. Suvorexant for the treatment of primary insomnia: a systematic review and meta-analysis
HRP20100014T1 (hr) Uporaba il-23 i il-17 antagonista u liječenju autoimune očne upalne bolesti
TWI738648B (zh) 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物
JP2017160178A5 (https=)
JP2010509369A5 (https=)
Khan et al. Tramadol use in premature ejaculation: daily versus sporadic treatment
CN111372948A (zh) 用il-17拮抗剂治疗化脓性汗腺炎
JP7309816B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
JP2018515493A5 (https=)
KR20220112803A (ko) 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US20210386712A1 (en) New use of angiotensin ii type 2 receptor agonist
JP2018534259A5 (https=)
CN115697378A (zh) 用cgrp抑制剂治疗肺部损伤的方法
Saco et al. Prurigo nodularis: Picking the right treatment.
WO2013165590A1 (en) Methods for treating idiopathic pulmonary fibrosis
KR20180017145A (ko) 소양증의 치료
KR20230054444A (ko) 호흡기 질환 치료에 사용하기 위한 (1r,3s)-3-((5-시아노-4-페닐티아졸-2-일)카바모일)사이클로펜탄-1-카르복시산 및 이의 유도체
JP2023182632A (ja) 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
AU2015305430A1 (en) Method for treating hyperhidrosis
Lewis et al. Oral gold: a comparison with placebo and with intramuscular sodium aurothiomalate
Srinivasu et al. Lack of pharmacokinetic interaction between sumatriptan and naproxen
JPWO2020039256A5 (https=)
Skoner Montelukast in 2‐to 5‐year‐old children with asthma
HK40104675A (zh) 异位性皮肤炎的治疗